Entervax (oral enteric fever vaccine) / Prokarium - LARVOL DELTA

Engineering a Novel Bivalent Oral Vaccine against Enteric Fever. (PubMed, Int J Mol Sci) - P1 | "A formulation containing both ZH9 and ZH9PA strains together constitutes a new bivalent vaccine candidate that targets both S. Typhi and S. Paratyphi A antigens to address a major global healthcare gap for enteric fever prophylaxis. This vaccine is now being tested in a Phase I clinical trial (NCT04349553)."

Journal

Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine (clinicaltrials.gov) - P1; N=46; Completed; Sponsor: Prokarium Ltd; Recruiting ➔ Completed; Trial completion date: Sep 2020 ➔ Feb 2021; Trial primary completion date: May 2020 ➔ Sep 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date